Hims & Hers Health swings to Q1 net loss on restructuring charges, GLP-1 strategic pivot

Hims & Hers Health

11/05/2026 21:15

Overview

U.S. health platform's Q1 revenue rose 4% yr/yr, missing analyst expectations

Company posted a net loss of $92.1 mln, compared to net income last year

Full-year 2026 revenue guidance raised to $2.8 bln-$3.0 bln

Outlook

Hims & Hers raises 2026 full-year revenue guidance to $2.8 bln-$3.0 bln

Company updates 2026 adjusted EBITDA guidance to $275 mln-$350 mln

Company expects Q2 2026 revenue of $680 mln-$700 mln

Result Drivers

SUBSCRIBER GROWTH - Co said subscribers grew 9% yr/yr to nearly 2.6 mln, broadening consumer reach

INTERNATIONAL EXPANSION - Rest of the World revenue rose sharply, offsetting a decline in U.S. revenue

GLP-1 PRODUCT STRATEGY - Co made a strategic pivot to expand branded GLP-1 offerings, aiming to boost consumer reach

Company press release: ID:nBw32n6VGa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$608 mln
$616.85 mln (13 Analysts)
Q1 EPS
-$0.40
Q1 Net Income
-$92.1 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Hims & Hers Health Inc is $25.00, about 11.6% below its May 8 closing price of $28.27

The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 48 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)